cathepsin-g and aloxistatin

cathepsin-g has been researched along with aloxistatin* in 3 studies

Other Studies

3 other study(ies) available for cathepsin-g and aloxistatin

ArticleYear
Regulation of cathepsin G reduces the activation of proinsulin-reactive T cells from type 1 diabetes patients.
    PloS one, 2011, Volume: 6, Issue:8

    Autoantigenic peptides resulting from self-proteins such as proinsulin are important players in the development of type 1 diabetes mellitus (T1D). Self-proteins can be processed by cathepsins (Cats) within endocytic compartments and loaded to major histocompatibility complex (MHC) class II molecules for CD4(+) T cell inspection. However, the processing and presentation of proinsulin by antigen-presenting cells (APC) in humans is only partially understood. Here we demonstrate that the processing of proinsulin by B cell or myeloid dendritic cell (mDC1)-derived lysosomal cathepsins resulted in several proinsulin-derived intermediates. These intermediates were similar to those obtained using purified CatG and, to a lesser extent, CatD, S, and V in vitro. Some of these intermediates polarized T cell activation in peripheral blood mononuclear cells (PBMC) from T1D patients indicative for naturally processed T cell epitopes. Furthermore, CatG activity was found to be elevated in PBMC from T1D patients and abrogation of CatG activity resulted in functional inhibition of proinsulin-reactive T cells. Our data suggested the notion that CatG plays a critical role in proinsulin processing and is important in the activation process of diabetogenic T cells.

    Topics: Blotting, Western; Carrier Proteins; Cathepsin G; Cell-Penetrating Peptides; Cells, Cultured; Diabetes Mellitus, Type 1; Enzyme-Linked Immunosorbent Assay; Humans; Leucine; Pepstatins; Polymerase Chain Reaction; Proinsulin; T-Lymphocytes

2011
A thiol proteinase inhibitor, E-64-d, corrects the abnormalities in concanavalin A cap formation and the lysosomal enzyme activity in leucocytes from patients with Chediak-Higashi syndrome by reversing the down-regulated protein kinase C activity.
    Clinical and experimental immunology, 2001, Volume: 125, Issue:2

    We have reported previously that the abnormally down-regulated protein kinase C (PKC) causes cellular dysfunction observed in natural killer (NK) cells, polymorphonuclear leucocytes (PMNs) and fibroblasts from beige mouse, an animal model of Chediak-Higashi syndrome (CHS). Here we show that the abnormal down-regulation of PKC activity also occurs in Epstein-Barr (EB) virus-transformed cell lines from CHS patients. When CHS cell lines were stimulated with concanavalin A (Con A) for 20 min, the membrane-bound PKC activity declined markedly, whereas that in control cell lines increased. We found that E-64-d, which protects PKC from calpain-mediated proteolysis, reversed the declined PKC activity and corrected the increased Con A cap formation to almost normal levels in CHS cell lines. We confirmed that the dysregulation of PKC activity also occurred in peripheral blood mononuclear leucocytes (PBMC) from CHS patients and that E-64-d corrected both the declined PKC activity and increased Con A cap formation. E-64-d also corrected the reduced lysosomal elastase and cathepsin G activity in CHS cell lines. In contrast, chelerythrin, a specific inhibitor of PKC, and C2-ceramide, which promotes PKC breakdown induced by calpain, increased Con A cap formation and inhibited both elastase and cathepsin G activity in normal cell lines. Moreover, we found that ceramide production in CHS cell lines increased significantly after Con A stimulation, which coincides with our previous observation in fibroblasts from CHS mice. These results suggest an association between ceramide-induced PKC down-regulation and the cellular dysfunctions in CHS.

    Topics: Calpain; Cathepsin G; Cathepsins; Cell Line, Transformed; Ceramides; Chediak-Higashi Syndrome; Child; Concanavalin A; Cysteine Proteinase Inhibitors; Down-Regulation; Drug Antagonism; Female; Humans; Leucine; Leukocytes, Mononuclear; Lysosomes; Male; Pancreatic Elastase; Protein Kinase C; Receptor Aggregation; Serine Endopeptidases; Sphingomyelin Phosphodiesterase

2001
Abnormal down-regulation of PKC is responsible for giant granule formation in fibroblasts from CHS (beige) mice--a thiol proteinase inhibitor, E-64-d, prevents giant granule formation in beige fibroblasts.
    Journal of leukocyte biology, 2000, Volume: 67, Issue:5

    We have previously reported that the abnormally rapid down-regulation of protein kinase C (PKC) activity is responsible for the cellular dysfunction in natural killer (NK) cells and polymorphonuclear leukocytes (PMNs) from Chediak-Higashi syndrome (beige) mice. In this report, we examined whether the down-regulation of PKC is associated with giant granule formation in fibroblasts from beige mice. In cultured beige fibroblasts, the membrane-bound PKC activity declined significantly after phorbol ester stimulation. We found that E-64-d, which is a thiol proteinase inhibitor and protects PKC from calpain-mediated proteolysis, reversed the declined PKC activity and prevented giant granule formation in beige fibroblasts. Moreover, E-64-d corrected the reduced lysosomal elastase and cathepsin G activity in beige fibroblasts. In contrast, specific PKC inhibitors, chelerythrin and calphostin C, promoted giant granule formation in normal fibroblasts. We also demonstrate that ceramide production is enhanced in beige fibroblasts and is involved in the rapid down-regulation of PKC. These results suggest that the accelerated breakdown of PKC observed in beige fibroblasts is caused by enhanced ceramide production and is also responsible for giant granule formation.

    Topics: Animals; Cathepsin G; Cathepsins; Cells, Cultured; Ceramides; Chediak-Higashi Syndrome; Cysteine Proteinase Inhibitors; Cytoplasmic Granules; Cytosol; Embryo, Mammalian; Fibroblasts; Leucine; Lysosomes; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pancreatic Elastase; Protein Kinase C; Serine Endopeptidases; Sphingolipids; Tetradecanoylphorbol Acetate

2000